ESMO 2018 | IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

In this video, Peter Schmid, MD, FRCP, PhD, of the Barts Cancer Institute, London, UK, discusses the key outcomes of the IMpassion130 study (NCT02425891); the first Phase III study featuring atezolizumab in combination with chemotherapy (nab-placlitaxel) to show significant improvement in overall survival and progression-free survival in the intention-to-treat (ITT) and PD-L1+ patient populations with metastatic triple-negative breast cancer (mTNBC). Prof. Schmid was speaking at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.